title: Insulin pump for the treatment of diabetes in combination with ulcerative foot infections.
abstract: Ulcerative foot infection is a chronic complication frequently seen in diabetic patients, and can result in disability. To evaluate insulin pump treatment for type 2 diabetes in combination with ulcerative foot infection, we selected 168 diabetic patients who developed foot ulcers and received treatment from April 2012 to April 2014 in the Peoples Hospital of Zhengzhou, Henan, China. The patients were divided into a treatment group and a control group, 84 in each group. Besides anti-infection treatment, patients in the control group were given multiple subcutaneous insulin injection (MSII), while patients in the treatment group were given continuous subcutaneous insulin infusion (CSII). Ulcer area, fasting plasma glucose (FPG), C-reactive protein (CRP) and count of white blood cells (WBC) were recorded before treatment, one week after treatment, two weeks after treatment and four weeks after treatment; moreover, ulcer healing condition was recorded four weeks after treatment and the related factors were analyzed. Patients in the treatment group showed an obviously narrowed ulcer area two and four weeks after treatment (P less than 0.05) and significantly lowered levels of FPG, CRP and WBC in the 1st, 2nd and 3rd weeks after treatment (P less than 0.05); four weeks after treatment, 88.1% of patients in the treatment group and 66.7% in the control group had healed well, and the difference between two groups was statistically significant (χ2=5.509, P=0.019). Multi-factor logistic regression analysis indicated that levels of FPG, CRP and WBC at baseline and four weeks after treatment had a positive correlation to ulcer healing (P less than 0.05). All the above findings suggest that insulin pump can improve ulcer healing of patients suffering from diabetic foot ulcers as it effectively controls blood glucose level, restrains inflammatory reaction and prevents spreading of infection.
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: H J
authors.initials: HJ
authors.lastname: Fan
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: J H
authors.initials: JH
authors.lastname: Yu
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: G M
authors.initials: GM
authors.lastname: Cui
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: W Y
authors.initials: WY
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Endocrinology, Peoples Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: Q J
authors.initials: QJ
authors.lastname: Dong
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017719:Diabetic Foot / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007332:Insulin Infusion Systems; D016015:Logistic Models; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D002097:C-Reactive Protein